Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States

Nom du journal : J Natl Cancer Inst

Année : 2016

Volume : 108

Page de départ : 108 (7)

Auteurs: Padula WV, Larson RA, Dusetzina SB, Apperley JF, Hehlmann R, Baccarani M, Eigendorff E, Guilhot J, Guilhot F, Hehlmann R, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Saußele S, Schiffer CA, Silver RT, Simonsson B, Conti RM, Conti RM,